Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seattle Genetics Inc.

Latest From Seattle Genetics Inc.

ADC Therapeutics Raises $76m To Keep ADC Development Momentum Going

The company extended its series E financing to $276m to keep its two lead ADC candidates moving toward pivotal data and BLA filings, including a planned filing for ADCT-402 late next year. The funding news comes as the ADC field moves into the spotlight.

Financing Cancer

So Far, Still So Good For Seattle Genetics/Astellas’ Bladder Cancer ADC

Updated data from the Phase II EV-201 study of Seattle Genetics/Astellas Pharma’s novel ADC are strong enough to warrant accelerated approval, its investigators claim. An accelerated submission to the US FDA is due later this year.

ASCO Clinical Trials

Lung Cancer, Conjugates Emerge As Key Asia Company Themes

Among Asia Pacific pharma companies presenting new clinical data on their oncology pipelines at ASCO, lung and urothelial cancer and antibody-drug conjugates emerge as stand-out themes.

ASCO Cancer

Genmab Plots $500m Nasdaq IPO

Some 20 years after its birth, the Danish biotech has decided the time is right to go west and raise cash through a US listing to drive its pipeline forward.

Financing Business Strategies
See All

Company Information